Bio­gen's full Ph2 da­ta for IgA nephropa­thy drug; Sanofi in­vests in obe­si­ty biotech

Plus, news about No­var­tis, Com­bi­Gene, Pro­QR and Aard­vark Ther­a­peu­tics:

Bio­gen presents full Phase 2 da­ta for felzartam­ab: The drug, which was ac­quired in Bio­gen’s …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER